Atyr Pharma Inc. (NASDAQ:LIFE) shares saw unusually-high trading volume on Monday . Approximately 537,577 shares changed hands during mid-day trading, an increase of 35% from the previous session’s volume of 399,269 shares.The stock last traded at $3.69 and had previously closed at $3.42.

LIFE has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday. Zacks Investment Research raised Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Tuesday, May 31st. Finally, BMO Capital Markets reissued a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Atyr Pharma has an average rating of “Hold” and an average target price of $6.75.

The company’s market cap is $86.69 million. The company has a 50-day moving average of $2.96 and a 200-day moving average of $3.72.

Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.06. On average, equities research analysts predict that Atyr Pharma Inc. will post ($2.73) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Atyr Pharma stock. RS Investment Management Co. LLC raised its stake in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned about 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.